SUMMARY. A new approach has been developed for bioequivalence testing to avoid imprac-tical rejections which may occur with the commonly used Westlake’s (1972) symmetric interval procedure. These methods are shown to cover the original symmetric confidence interval approach as a special case. Also, it is of considerable interest from the manufacturer’s point of view, to ob-tain the minimum sample size which guarantees a pre-specified power to the test. The calculation of this minimum sample size accounts for the plausible asymmetry in the equivalence range and plausible non-zero expected value of the true difference. Algorithms are provided with illustrations for both testing and sample size problems. 1
The statistical test of the hypothesis of no difference between the average bioavailabilities of two...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Reference-scaled average bioequivalence (RSABE) has been recommended by Food and Drug Administratio...
In 1992, the US Food and Drug Administration declared that two drugs demonstrate average bioequivale...
The currently accepted statistical method for declaring bioequivalence (BE) is the Classical 90 % Co...
[[abstract]]The approval of generic drugs requires the evidence of average bioequivalence (ABE) on b...
A new procedure is proposed to test the interval hypothesis, which tests whether the mean of a popul...
A simple three-step approach for the assessment of bioequivalence is proposed. According to the deci...
We consider the comparison of two formulations in terms of average bioequivalence using the 2 × 2 cr...
It is shown that the standard two one-sided tests procedure for bioe-quivalence is a biased test. Be...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Bioequivalence (BE) means the absence of a greater-than-allowable difference between the systemic bi...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
It is shown that the standard two one-sided tests procedure for bioequivalence is a biased test. Bet...
We will study here a general method for constructing equivalence tests for problems with onedimensio...
The statistical test of the hypothesis of no difference between the average bioavailabilities of two...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Reference-scaled average bioequivalence (RSABE) has been recommended by Food and Drug Administratio...
In 1992, the US Food and Drug Administration declared that two drugs demonstrate average bioequivale...
The currently accepted statistical method for declaring bioequivalence (BE) is the Classical 90 % Co...
[[abstract]]The approval of generic drugs requires the evidence of average bioequivalence (ABE) on b...
A new procedure is proposed to test the interval hypothesis, which tests whether the mean of a popul...
A simple three-step approach for the assessment of bioequivalence is proposed. According to the deci...
We consider the comparison of two formulations in terms of average bioequivalence using the 2 × 2 cr...
It is shown that the standard two one-sided tests procedure for bioe-quivalence is a biased test. Be...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Bioequivalence (BE) means the absence of a greater-than-allowable difference between the systemic bi...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
It is shown that the standard two one-sided tests procedure for bioequivalence is a biased test. Bet...
We will study here a general method for constructing equivalence tests for problems with onedimensio...
The statistical test of the hypothesis of no difference between the average bioavailabilities of two...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Reference-scaled average bioequivalence (RSABE) has been recommended by Food and Drug Administratio...